<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573923</url>
  </required_header>
  <id_info>
    <org_study_id>Alliancells-2012-1</org_study_id>
    <nct_id>NCT01573923</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis</brief_title>
  <acronym>LC</acronym>
  <official_title>Clinical Trial of Umbilical Mesenchymal Stem Cells Transplantation for Liver Cirrhosis-Phase I/II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliancells Bioscience Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alliancells Bioscience Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis and subsequent liver failure are leading causes of morbidity and mortality
      worldwide. Alcohol abuse and viral hepatitis are the most common causes of cirrhosis. Novel
      therapies are necessary to prevent or block the process of the disease. In this current
      prospective cohort, the investigators plan to organize four hospitals to determine the safety
      and efficacy of intravenous administration of umbilical mesenchymal stem cells in the
      treatment of patients with liver cirrhosis in next three years.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival time</measure>
    <time_frame>3-year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum markers regarding liver and kidney function</measure>
    <time_frame>0, 3, 6, 9 and 12 months</time_frame>
    <description>liver functions：Albumin (ALB), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), Prealbumin(PA), total bilirubin (TB), and direct bilirubin (DB) kidney function：Blood urea nitrogen (BUN), Urea (UA), and Crea (Cr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers regarding lipid and sugar profile</measure>
    <time_frame>0, 3, 6, 9 and 12 months</time_frame>
    <description>Total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), very low density lipoprotein cholesterol (VLDL-C), and Non-HDL-C; blood sugar;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers regarding cytokine profile</measure>
    <time_frame>0, 3, 6, 9 and 12 months</time_frame>
    <description>IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12(p40), IL-15, IL-17A, TNFα, TNFβ, IFN-γ, RANTES, TGFβ, lymphotactin, and C-reactive protein level (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Hepatitis B and C</measure>
    <time_frame>0, 3, 6, 9 and 12 months</time_frame>
    <description>Serum levels of Hepatitis B and C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance and the adverse events</measure>
    <time_frame>3-year follow up</time_frame>
    <description>The classification for uncomfortable reaction is: 0, no discomfort; 1, slightly unwell, does not affect daily life; 2, moderate discomfort, affects daily life and work; 3, moderately unwell, significantly affects life, and bed rest; 4, severely unwell, life-threatening.
A serious adverse event is defined as fatal, life threatening, permanently disabling, and tumors, particularly hepatocellular carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of any clinical symptoms</measure>
    <time_frame>3-year follow up</time_frame>
    <description>abdominal distension, appetite, debilitation, and edema of lower limbs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Conventional therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>only apply for conventional medical therapy without any cell therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Conventional therapy without cell therapy</description>
    <arm_group_label>Conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  aged 30-60 years

          -  clinical diagnosis of compensated or decompensated liver

          -  child-Pugh B/C (7-12 points)

          -  expecting lifetime is over three years

        Exclusion Criteria:

          -  pregnant woman

          -  patient with severe vascular diseases

          -  patient with any organ failure

          -  patient with any tumors

          -  patient with HIV

          -  patient who has been transplanted

          -  patient treated with immunosuppressors

          -  patient for whom the follow-up is considered impossible

          -  patients with any disease or condition which the investigator or treating physician
             feels would interfere with the trial or the safety of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuetao Pei, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese Industry and Innovative Technology Strategic Alliance of Stem Cells and Regenerative Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongjun Liu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alliancells Bioscience Corporation Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mingyuan Wu, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eastern Union Stem Cell &amp; Gene Engineering Co.,Ltd， Alliancells Bioscience Corporation Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanwei Li, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 302 Hospital of Chinese People's Liberation Army</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liming Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 323 Hospital of Chinese People's Liberation Army</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xun Li, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liming Chen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ongji Hospital of Tongji University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianwei Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital of Tongji University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First People's Hospital of Lianyungang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuetao Pei, MD,PhD</last_name>
    <phone>86-10-68214650</phone>
    <email>peixt@nic.bmi.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haijie Ji, MD</last_name>
    <phone>86-10-63188853</phone>
    <email>jihaijie82@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The 302 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hanwei Li, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Li, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xun Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan BOAO Life infinity international anti-aging medical center</name>
      <address>
        <city>Qionghai</city>
        <state>Hainan</state>
        <zip>571434</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Shu</last_name>
      <email>Jiang.st@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first people's hospital of Lianyungang</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Shi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hui Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liming Chen, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jianwei Lu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 323 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liming Wang, MD</last_name>
      <phone>86-29-84756502</phone>
      <email>wanglm@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Liming Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>April 12, 2015</last_update_submitted>
  <last_update_submitted_qc>April 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Umbilical Mesenchymal Stem Cells; Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

